Ibrutinib: Indication of added benefit in one of three therapeutic indications

No added benefit has been proven for chronic lymphocytic leukaemia and Waldenström macroglobulinaemia. Certain patients with relapsed or refractory mantle cell lymphoma benefit from the drug.